"Endless is the search for truth." – Laurence Sterne
Cardiogenic shock (CS) presently accounts for approximately 15% of all cardiac intensive care unit admissions, and inpatient mortality rates remain high at ≥50% despite several decades of advances in pharmacologic and device-based therapies and systems of care [ ]. The complexity of the CS syndrome, delays in CS recognition, barriers to access to potentially disease-modifying interventions, and undesired heterogeneities of care within and between medical facilities all likely contribute to the persistent lethality of CS. There are also multiple converging paths to death with both shock-related and shock-independent factors that significantly impact CS severity and mortality – to include age, cardiac arrest, respiratory failure, anoxic brain injury, organ failure, and bleeding [ ]. All of this complicates much-needed efforts to better and more uniformly define CS severity, stage, and phenotype and match the “right” patients to the “best” therapies at the most appropriate times and locations.
Cardiovascular Revascularization Medicine, 2021-10-01, Volume 31, Pages 76-77
Read the full article on Science Direct: https://www.clinicalkey.com/#!/content/playContent/1-s2.0-S1553838921004991?returnurl=null&referrer=null